Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.53 -4.1%	$1.16	$0.65 ▼ $26.25	$16.96M	1.23	802,144 shs	496,369 shs
DRMA Dermata Therapeutics	$0.68 -0.9%	$0.71	$0.57 ▼ $5.00	$4.36M	0.54	1.18 million shs	60,264 shs
HOTH Hoth Therapeutics	$1.25 -6.7%	$1.15	$0.58 ▼ $3.80	$17.70M	0.67	3.73 million shs	391,829 shs
RVPH Reviva Pharmaceuticals	$0.40 -1.5%	$0.70	$0.30 ▼ $4.28	$19.45M	-0.06	1.46 million shs	1.55 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	+7.05%	-2.15%	+86.92%	+64.77%	-92.22%
DRMA Dermata Therapeutics	-2.57%	-5.10%	-3.48%	-6.31%	-65.68%
HOTH Hoth Therapeutics	0.00%	-10.07%	+3.08%	+70.14%	+42.57%
RVPH Reviva Pharmaceuticals	+5.58%	+3.37%	-43.72%	-48.21%	-66.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	3.0736 of 5 stars	3.3	4.0	3.0	0.8	1.3
DRMA Dermata Therapeutics	2.2771 of 5 stars	3.5	4.0	2.0	0.8	0.0
HOTH Hoth Therapeutics	3.1685 of 5 stars	3.6	5.0	3.3	0.0	0.6
RVPH Reviva Pharmaceuticals	3.3938 of 5 stars	3.6	2.0	3.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,355.02% Upside
DRMA Dermata Therapeutics	3.00	Buy	$3.00	343.13% Upside
HOTH Hoth Therapeutics	3.25	Buy	$4.00	217.46% Upside
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	2,167.00% Upside

Current Analyst Ratings Breakdown

Latest DRMA, RVPH, HOTH, and CTXR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
5/15/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$10.25 per share	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.23	N/A	N/A	-58.63%	-37.67%	8/11/2025 (Estimated)
DRMA Dermata Therapeutics	-$12.29M	-$16.41	N/A	∞	N/A	N/A	-270.81%	-179.96%	8/6/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.79	N/A	N/A	N/A	N/A	N/A	-302.31%	8/13/2025 (Estimated)

Latest DRMA, RVPH, HOTH, and CTXR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	N/A	N/A	N/A	$1.92 million	N/A
8/8/2025	N/A	HOTH Hoth Therapeutics	-$0.27	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
5/14/2025	Q2 2025	CTXR Citius Pharmaceuticals	-$1.08	-$1.27	-$0.19	-$1.27	N/A	N/A
5/14/2025	Q1 2025	DRMA Dermata Therapeutics	-$0.45	-$0.45	N/A	-$0.45	N/A	N/A
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.37	0.06
DRMA Dermata Therapeutics	N/A	3.70	3.70
HOTH Hoth Therapeutics	N/A	15.09	15.08
RVPH Reviva Pharmaceuticals	N/A	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
DRMA Dermata Therapeutics	8.67%
HOTH Hoth Therapeutics	7.08%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
DRMA Dermata Therapeutics	18.50%
HOTH Hoth Therapeutics	6.92%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
DRMA Dermata Therapeutics	8	6.38 million	5.20 million	Not Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

DRMA, RVPH, HOTH, and CTXR Headlines

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

March 31, 2025 | markets.businessinsider.com

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

March 30, 2025 | globenewswire.com

Why Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%

March 7, 2025 | aaii.comA

Unusually active option classes on open February 12th

February 12, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA, RVPH, HOTH, and CTXR Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.53 -0.07 (-4.08%)

Closing price 04:00 PM Eastern

Extended Trading

$1.59 +0.06 (+3.92%)

As of 07:50 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Dermata Therapeutics NASDAQ:DRMA

$0.68 -0.01 (-0.88%)

Closing price 03:49 PM Eastern

Extended Trading

$0.65 -0.03 (-3.84%)

As of 05:58 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Hoth Therapeutics NASDAQ:HOTH

$1.25 -0.09 (-6.72%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 +0.00 (+0.40%)

As of 07:55 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.40 -0.01 (-1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 +0.00 (+0.48%)

As of 07:47 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time